ACTG A5186 FISH OIL AND FENOFIBRATE IN SUBJECTS ON HAART

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。在hiv感染治疗中使用蛋白酶抑制剂（pi）与脂质异常相关，其中最显著的是血清极低密度脂蛋白（VLDL）甘油三酯升高。这在含有利托那韦的方案中最常见，但其他pi，如奈非那韦，也可以引起这些脂质变化。也许最令人担忧的是，越来越多的证据表明，一些与艾滋病毒/抗逆转录病毒治疗相关的代谢紊乱可能加速动脉粥样硬化的发展，导致缺血性心脑血管疾病的发病率更高。欧米伽-3脂肪酸用于治疗高甘油三酯血症已有二十多年了，欧米伽-3脂肪酸对心血管健康的有益作用来自于对格陵兰爱斯基摩人的观察，他们的饮食中含有欧米伽-3脂肪酸的脂肪，冠心病和中风的发病率很低。本研究的假设是，鱼油补充剂或非诺贝特单独治疗不足以治疗大多数HAART患者的高甘油三酯，而鱼油补充剂与非诺贝特联合治疗在降低血清甘油三酯方面的效果明显优于单独治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The use of protease inhibitors (PIs), in the treatment of HIV-infection is associated with lipid abnormalities that include most prominently elevations in serum very low-density lipoprotein (VLDL) triglycerides. This is most frequently observed with ritonavir-containing regimens, but other PIs, like nelfinavir, can cause these lipid changes as well. Perhaps the most significant concern is the mounting evidence that some HIV/antiretroviral treatment-associated metabolic disturbances may accelerate the development of athrerosclerosis leading to higher rates of ischemic cardiovascular and cerebrovascular disease. Omega-3 fatty acids have been used for the treatment of hypertriglyceridemia for over two decades the salutary effect of omega-3 fatty acids on cardiovascular health came from the observation that Greenland Eskimos, whose diet contains fat with omega-3 fatty acids, have a low incidence of coronary heart disease and strokes. The hypothesis of this study is that fish oil supplement or fenofibrate alone are inadequate to treat the majority of persons on HAART with hypertriglyceridema, and the combination of fish oil supplement with fenofibrate will result in a significantly improved efficacy in lowering serum triglycerides compared to either therapy alone.